Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer

BJU International

Volumn 86, Issue 6, 2000, Pages 742-748

  Hrouda, D ^a,c   Todryk, S M ^a   Perry, M J A ^a,c   Souberbielle, B E ^a,b,c   Kayaga, J ^a   Kirby, R S ^a,c   Dalgleish, A G ^a,d  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Allogeneic vaccine; Immunotherapy; Prostate cancer; Rat model

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER REGRESSION; CANCER SURVIVAL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; VACCINATION;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MYCOBACTERIUM; PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED;

EID: 0033772075     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00887.x     Document Type: Article

References (29)

1. Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 1984; 5: 19-23
2. Schellhammer PF, El-Mahdi AM, Higgins EM, Schultheis TE, Ladaga LE, Babb TJ. Prostate biopsy after definitive treatment by interstitial iodine 125 implant or external beam radiation therapy. J Urol 1987; 137: 897-901
3. Huggins C, Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
4. Crawford ED, Blumenstein BA, Goodman PJ et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66: 1039-44
5. Harris DT, Matyas GR, Gomella LG et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 1999; 26: 439-47
6. Guinan P, Toronchi E, Shaw M, Crispin R, Sharifi R. Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 1982; 20: 401-3
7. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82: 568-73
8. Moody DB, Robinson JC, Ewing CM. Lazenby AJ, Isaacs WB. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994; 24: 244-51
9. Sanda MG, Ayyagari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-8
10. Vieweg J, Rosenthal FM, Bannerji R et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-5
11. Hrouda D, Souberbielle BE, Kayaga J, Corbishley CM, Kirby RS, Dalgleish AG. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 1998; 82: 870-6
12. Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-8
13. Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 1986; 22: 82-90
14. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Med Res 1996; 6: 299-306
15. Souberbielle BE, Westby M, Ganz S et al. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther 1998; 5: 1447-54
16. Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82
17. Dalgleish AG, Souberbielle BE. The development of therapeutic vaccines of the management of malignant melanoma. Cancer Surv 1996; 26: 289-319
18. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242-3
19. Eibl B, Schwaighofer H, Nachbaur D et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-8
20. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46: 681-6
21. Sarosdy MF. Oral bropirimine immunotherapy of rodent prostate cancer. Eur Urol 1997; 31: 5-9
22. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate I. Untreated patients. J Urol 1989; 141: 1070
23. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4: 295-302
24. Newhall KR, Isaacs JT, Wright GL. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens. Prostate 1990; 17: 317-25
25. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-32
26. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5
27. Maass G, Schmidt W, Berger M et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995; 92: 5540-4
28. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci USA 1993; 90: 3539-43
29. Kayaga J, Souberbielle B, Sheikh N et al. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 1999; 6: 1475-81